Tufts: Biologics Manufacturers Need More Adaptable Strategies

International Pharmaceutical Regulatory Monitor
A A
Makers of biopharmaceuticals will need to become more modular and agile to adjust for trends in personalized medicine and oncology, according to the Tufts Center for the Study of Drug Development.

To View This Article:

Login

Subscribe To International Pharmaceutical Regulatory Monitor